157 related articles for article (PubMed ID: 38185013)
1. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.
Kraft FB; Enns J; Honin I; Engelhardt J; Schöler A; Smith ST; Meiler J; Schäker-Hübner L; Weindl G; Hansen FK
Bioorg Chem; 2024 Feb; 143():107072. PubMed ID: 38185013
[TBL] [Abstract][Full Text] [Related]
2. First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.
Yue K; Sun S; Jia G; Qin M; Hou X; Chou CJ; Huang C; Li X
J Med Chem; 2022 Sep; 65(18):12140-12162. PubMed ID: 36073117
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release.
Bockstiegel J; Wurnig SL; Engelhardt J; Enns J; Hansen FK; Weindl G
Biochem Pharmacol; 2023 Sep; 215():115693. PubMed ID: 37481141
[TBL] [Abstract][Full Text] [Related]
4. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
Jha S; Kim JH; Kim M; Nguyen AH; Ali KH; Gupta SK; Park SY; Ha E; Seo YH
Eur J Med Chem; 2024 Feb; 265():116057. PubMed ID: 38142511
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
[TBL] [Abstract][Full Text] [Related]
8. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6.
Cao Z; Gu Z; Lin S; Chen D; Wang J; Zhao Y; Li Y; Liu T; Li Y; Wang Y; Lin H; He B
ACS Chem Biol; 2021 Dec; 16(12):2746-2751. PubMed ID: 34860497
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma.
Peng X; Yu Z; Surineni G; Deng B; Zhang M; Li C; Sun Z; Pan W; Liu Y; Liu S; Yu B; Chen J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2201408. PubMed ID: 37096557
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Kong SJ; Nam G; Boggu PR; Park GM; Kang JE; Park HJ; Jung YH
Bioorg Med Chem; 2023 Feb; 79():117154. PubMed ID: 36645952
[TBL] [Abstract][Full Text] [Related]
12. Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
Chen P; Zhao LJ; Huang L; He WQ; Tang YR; Liu Y; Ren JD
Inflamm Res; 2023 Sep; 72(9):1919-1932. PubMed ID: 37725105
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of nigranoic acid and manwuweizic acid derivatives as HDAC inhibitors and anti-inflammatory agents.
Ni DX; Wang Q; Li YM; Cui YM; Shen TZ; Li XL; Sun HD; Zhang XJ; Zhang R; Xiao WL
Bioorg Chem; 2021 Apr; 109():104728. PubMed ID: 33636436
[TBL] [Abstract][Full Text] [Related]
15. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
17. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
Reßing N; Marquardt V; Gertzen CGW; Schöler A; Schramm A; Kurz T; Gohlke H; Aigner A; Remke M; Hansen FK
Medchemcomm; 2019 Jul; 10(7):1109-1115. PubMed ID: 31391882
[TBL] [Abstract][Full Text] [Related]
20. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
